Hepatic gene expression and functional changes associated with nonalcoholic steatohepatitis

Matsumoto,Kana; Kato,Yumiko; Hayashi,Momone; Miura,Risa; Monzen,Satoru; Chiba,Mitsuru

doi:10.3892/mmr.2022.12841

Hepatic gene expression and functional changes associated with nonalcoholic steatohepatitis

Authors:
- Kana Matsumoto
- Yumiko Kato
- Momone Hayashi
- Risa Miura
- Satoru Monzen
- Mitsuru Chiba
View Affiliations

Affiliations: Department of Bioscience and Laboratory Medicine, Graduate School of Health Sciences, Hirosaki University, Hirosaki, Aomori 036‑8564, Japan, Department of Medical Technology, School of Health Sciences, Hirosaki University, Hirosaki, Aomori 036‑8564, Japan, Department of Radiation Sciences, Graduate School of Health Sciences, Hirosaki University, Hirosaki, Aomori 036‑8564, Japan
Published online on: September 1, 2022 https://doi.org/10.3892/mmr.2022.12841
Article Number: 325
Copyright: © Matsumoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑alcoholic steatohepatitis (NASH) is a pathological condition of the liver in which hepatocyte steatosis, invasion of inflammatory cells and hepatic injury occur without alcohol abuse. Despite the known risk of liver cancer and liver fibrosis that may progress to liver cirrhosis that exists with NASH, an understanding of related gene expression and associated functional changes remains insufficient. The present study used a mouse model of NASH induced by a high‑fat diet to examine gene expression in the liver and to search for transcripts that could predict early liver fibrosis in the future. Mice fed a high‑fat diet for 2 weeks showed typical NASH liver histology by hematoxylin and eosin staining, and increased fibrosis was confirmed by Sirius red staining after 6 weeks. Functional changes associated with liver damage, liver inflammation, liver steatosis and liver fibrosis were predicted by toxicological ontology analysis using Ingenuity Pathways Analysis. Downregulated microRNA (miR)‑21 and upregulated collagen type III α1 mRNA in the liver and upregulated exosomal miR‑21 in serum of mice fed a high‑fat diet for 1 and/or 2 weeks were confirmed by reverse transcription‑quantitative PCR, suggesting that these changes occur prior to histological confirmation of fibrosis. Therefore, it may be possible to predict future liver fibrosis by analyzing fibrosis‑related genes that shift prior to pathological findings.

View Figures

View References

1	Ratziu V, Bellentani S, Cortez-Pinto H, Day C and Marchesini G: A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 53:372–384. 2010. View Article : Google Scholar : PubMed/NCBI
2	Cotter TG and Rinella M: Nonalcoholic fatty liver disease 2020: The state of the disease. Gastroenterology. 158:1851–1864. 2020. View Article : Google Scholar : PubMed/NCBI
3	Balakrishnan M and Loomba R: The role of noninvasive tests for differentiating NASH from NAFL and diagnosing advanced fibrosis among patients with NAFLD. J Clin Gastroenterol. 54:107–113. 2020. View Article : Google Scholar : PubMed/NCBI
4	Ludwig J, Viggiano TR, McGill DB and Oh BJ: Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 55:434–438. 1980.PubMed/NCBI
5	Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC and McCullough AJ: Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. 116:1413–1419. 1999. View Article : Google Scholar : PubMed/NCBI
6	Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA and Bacon BR: Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol. 94:2467–2474. 1999. View Article : Google Scholar : PubMed/NCBI
7	Huang DQ, El-Serag HB and Loomba R: Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 18:223–238. 2021. View Article : Google Scholar : PubMed/NCBI
8	Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J and Vos MB: Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 69:2672–2682. 2019. View Article : Google Scholar : PubMed/NCBI
9	Argo CK, Northup PG, Al-Osaimi AM and Caldwell SH: Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 51:371–379. 2009. View Article : Google Scholar : PubMed/NCBI
10	Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K and Shiratori K: Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 24:248–254. 2009. View Article : Google Scholar : PubMed/NCBI
11	Nagai K, Kohno K, Chiba M, Pak S, Murata S, Fukunaga K, Kobayashi A, Yasue H and Ohkohchi N: Differential expression profiles of sense and antisense transcripts between HCV-associated hepatocellular carcinoma and corresponding non-cancerous liver tissue. Int J Oncol. 40:1813–1820. 2012.PubMed/NCBI
12	Tan Y, Ge G, Pan T, Wen D and Gan J: A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS One. 9:e1051922014. View Article : Google Scholar : PubMed/NCBI
13	Matsumoto M, Hada N, Sakamaki Y, Uno A, Shiga T, Tanaka C, Ito T, Katsume A and Sudoh M: An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int J Exp Pathol. 94:93–103. 2013. View Article : Google Scholar : PubMed/NCBI
14	Toita R and Kang JH: Long-term profile of serological biomarkers, hepatic inflammation, and fibrosis in a mouse model of non-alcoholic fatty liver disease. Toxicol Lett. 332:1–6. 2020. View Article : Google Scholar : PubMed/NCBI
15	Wang L, Jia XJ, Jiang HJ, Du Y, Yang F, Si SY and Hong B: MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition. Mol Cell Biol. 33:1956–1964. 2013. View Article : Google Scholar : PubMed/NCBI
16	Qadir XV, Chen W, Han C, Song K, Zhang J and Wu T: miR-223 deficiency protects against fas-induced hepatocyte apoptosis and liver injury through targeting insulin-like growth factor 1 receptor. Am J Pathol. 185:3141–3151. 2015. View Article : Google Scholar : PubMed/NCBI
17	Katsura A, Morishita A, Iwama H, Tani J, Sakamoto T, Tatsuta M, Toyota Y, Fujita K, Kato K, Maeda E, et al: MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis. Int J Mol Med. 35:877–884. 2015. View Article : Google Scholar : PubMed/NCBI
18	Kuivaniemi H and Tromp G: Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases. Gene. 707:151–171. 2019. View Article : Google Scholar : PubMed/NCBI
19	Huang Y, He Y and Li J: MicroRNA-21: A central regulator of fibrotic diseases via various targets. Curr Pharm Des. 21:2236–2242. 2015. View Article : Google Scholar : PubMed/NCBI
20	Loyer X, Paradis V, Hénique C, Vion AC, Colnot N, Guerin CL, Devue C, On S, Scetbun J, Romain M, et al: Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut. 65:1882–1894. 2016. View Article : Google Scholar : PubMed/NCBI
21	Becker PP, Rau M, Schmitt J, Malsch C, Hammer C, Bantel H, Müllhaupt B and Geier A: Performance of serum microRNAs −122, −192 and −21 as biomarkers in patients with non-alcoholic steatohepatitis. PLoS One. 10:e01426612015. View Article : Google Scholar : PubMed/NCBI